- Source: Glesatinib
Glesatinib (MGCD265) is an experimental anti-cancer drug.
It is in phase 2 clinical trials for non-small cell lung cancer (NSCLC).
It is a spectrum selective tyrosine kinase inhibitor "for the treatment of non-small cell lung cancer (NSCLC) patients with genetic alterations of MET".
See also
Mirati Therapeutics
References
External links
glesatinib@cancer.gov Archived 2017-01-16 at the Wayback Machine
